{"id":{"repo_id":"milano","oai_identifier":"oai:air.unimi.it:2434/1225595"},"canonical_url":"https://search.dev.ndltd.org/etd/milano/oai:air.unimi.it:2434/1225595","repository":{"repo_id":"milano","name":"Università degli Studi di Milano","base_url":"https://air.unimi.it/oai/request"},"display":{"title":"IMPACT OF SARS-COV-2 RESPIRATORY INFECTION ON CLINICAL OUTCOMES AND NEED FOR NON-INVASIVE VENTILATORY SUPPORT IN ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A SINGLE-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY","abstract":"Viral and bacterial infections are the main cause of COPD exacerbations, accounting for 25% and 26% of cases respectively. To date no conclusive data are available on the risk of COPD exacerbations triggered by SARS-CoV-2. The present study was primarily aimed to identify the risk of acute respiratory failure (ARF) requiring non-invasive respiratory support up to Continuous Positive Airway Pressure (C-PAP) and Non-Invasive Ventilation (NIV) in patients affected by SARS-CoV-2 triggered COPD exacerbation compared to patients with COPD exacerbations without SARS-CoV-2 infection. Major secondary endpoints included the overall risk of ARF and its stratification according to severity and consequent respiratory support needed. Mortality in the SARS-CoV-2 cohort was also compared to the control group. 238 COPD patients admitted to hospital due to an acute exacerbation of COPD were consecutively enrolled: 120 patients (50.4%) tested positive for SARS-CoV-2 infection at nasopharyngeal swab, while 118 (49.6%) were negative. No significant difference could be demonstrated in the risk of ARF between SARS-CoV-2 and control groups (Relative Risk (RR) 0.89 (p = 0.303), 95% Confidence Interval (CI): 0.73 – 1.06). However, the risk of ARF with the need of ventilatory support up to C-PAP was significantly higher in the SARS-CoV-2 group (RR 4.42 (p = 0.009), 95% CI 1.37 – 14.35).nOn the contrary, the risk of ARF needing NIV was 39% lower in the SARS-CoV-2 group (RR 0.61 (p = 0.003), 95% CI 0.44 – 0.84). This result combined with blood gas analysis values reflected a predominant hypoxemic ARF among SARS-CoV-2, differently from hypercapnic ARF in the control group. A significantly higher mortality rate was detected among SARS-CoV-2 patients at Kaplan-Meier survival analysis (1 year mortality: 33.33% in SARS-CoV-2 group vs 3.06% in controls, p <0.0001). Hospitalization was longer in SARS-CoV-2 group than controls (12 days, IQR 7.5–24.5 vs 9 days, IQR 7–14.25, p < 0.01). In conclusion, our study demonstrated that SARS-CoV-2 infection can be considered a potent trigger of COPD exacerbation, able to induce severe hypoxic ARF, which significantly increased the risk of needing positive pressure respiratory support. SARS-CoV-2 profoundly impacted on the mortality, meanwhile prolonging the length of hospital stay. Screening for the presence of viral triggers, particularly of SARS-CoV-2, in case of acute exacerbation of COPD is key, to influence clinical outcomes treatment approach and long-term survival.","abstract_html":"Viral and bacterial infections are the main cause of COPD exacerbations, accounting for 25% and 26% of cases respectively. To date no conclusive data are available on the risk of COPD exacerbations triggered by SARS-CoV-2. The present study was primarily aimed to identify the risk of acute respiratory failure (ARF) requiring non-invasive respiratory support up to Continuous Positive Airway Pressure (C-PAP) and Non-Invasive Ventilation (NIV) in patients affected by SARS-CoV-2 triggered COPD exacerbation compared to patients with COPD exacerbations without SARS-CoV-2 infection. Major secondary endpoints included the overall risk of ARF and its stratification according to severity and consequent respiratory support needed. Mortality in the SARS-CoV-2 cohort was also compared to the control group. 238 COPD patients admitted to hospital due to an acute exacerbation of COPD were consecutively enrolled: 120 patients (50.4%) tested positive for SARS-CoV-2 infection at nasopharyngeal swab, while 118 (49.6%) were negative. No significant difference could be demonstrated in the risk of ARF between SARS-CoV-2 and control groups (Relative Risk (RR) 0.89 (p = 0.303), 95% Confidence Interval (CI): 0.73 – 1.06). However, the risk of ARF with the need of ventilatory support up to C-PAP was significantly higher in the SARS-CoV-2 group (RR 4.42 (p = 0.009), 95% CI 1.37 – 14.35).nOn the contrary, the risk of ARF needing NIV was 39% lower in the SARS-CoV-2 group (RR 0.61 (p = 0.003), 95% CI 0.44 – 0.84). This result combined with blood gas analysis values reflected a predominant hypoxemic ARF among SARS-CoV-2, differently from hypercapnic ARF in the control group. A significantly higher mortality rate was detected among SARS-CoV-2 patients at Kaplan-Meier survival analysis (1 year mortality: 33.33% in SARS-CoV-2 group vs 3.06% in controls, p &lt;0.0001). Hospitalization was longer in SARS-CoV-2 group than controls (12 days, IQR 7.5–24.5 vs 9 days, IQR 7–14.25, p &lt; 0.01). In conclusion, our study demonstrated that SARS-CoV-2 infection can be considered a potent trigger of COPD exacerbation, able to induce severe hypoxic ARF, which significantly increased the risk of needing positive pressure respiratory support. SARS-CoV-2 profoundly impacted on the mortality, meanwhile prolonging the length of hospital stay. Screening for the presence of viral triggers, particularly of SARS-CoV-2, in case of acute exacerbation of COPD is key, to influence clinical outcomes treatment approach and long-term survival.","abstract_has_math":false,"creators":["TIRELLI, CLAUDIO"],"institution":"Università degli Studi di Milano","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["supervisor: M. Mondoni ; co-supervisor: S. Centanni ; coordinatore del corso di dottorato: M. Del Fabbro","C. Tirelli","MONDONI, MICHELE","DEL FABBRO, MASSIMO"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026-03-20","date_published":"2026-03-20","updated_at":"2026-07-27T20:19:00Z","subjects":["SARS-CoV-2","C-PAP","COPD","NIV","mortality","Settore MEDS-07/A - Malattie dell'apparato respiratorio"],"languages":["eng"],"rights":["info:eu-repo/semantics/openAccess","license:Creative commons","license uri:publisher"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2434/1225595","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["supervisor: M. Mondoni ; co-supervisor: S. Centanni ; coordinatore del corso di dottorato: M. Del Fabbro","C. Tirelli","MONDONI, MICHELE","DEL FABBRO, MASSIMO"]},{"key":"dc:creator","label":"Author","values":["TIRELLI, CLAUDIO"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2026-03-20"]},{"key":"dc:publisher","label":"Institution","values":["Università degli Studi di Milano"]},{"key":"dc:relation","label":"Dc Relation","values":["numberofpages:73"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["SARS-CoV-2","C-PAP","COPD","NIV","mortality","Settore MEDS-07/A - Malattie dell'apparato respiratorio"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess","license:Creative commons","license uri:publisher"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://hdl.handle.net/2434/1225595"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Viral and bacterial infections are the main cause of COPD exacerbations, accounting for 25% and 26% of cases respectively. To date no conclusive data are available on the risk of COPD exacerbations triggered by SARS-CoV-2. The present study was primarily aimed to identify the risk of acute respiratory failure (ARF) requiring non-invasive respiratory support up to Continuous Positive Airway Pressure (C-PAP) and Non-Invasive Ventilation (NIV) in patients affected by SARS-CoV-2 triggered COPD exacerbation compared to patients with COPD exacerbations without SARS-CoV-2 infection. Major secondary endpoints included the overall risk of ARF and its stratification according to severity and consequent respiratory support needed. Mortality in the SARS-CoV-2 cohort was also compared to the control group. 238 COPD patients admitted to hospital due to an acute exacerbation of COPD were consecutively enrolled: 120 patients (50.4%) tested positive for SARS-CoV-2 infection at nasopharyngeal swab, while 118 (49.6%) were negative. No significant difference could be demonstrated in the risk of ARF between SARS-CoV-2 and control groups (Relative Risk (RR) 0.89 (p = 0.303), 95% Confidence Interval (CI): 0.73 – 1.06). However, the risk of ARF with the need of ventilatory support up to C-PAP was significantly higher in the SARS-CoV-2 group (RR 4.42 (p = 0.009), 95% CI 1.37 – 14.35).nOn the contrary, the risk of ARF needing NIV was 39% lower in the SARS-CoV-2 group (RR 0.61 (p = 0.003), 95% CI 0.44 – 0.84). This result combined with blood gas analysis values reflected a predominant hypoxemic ARF among SARS-CoV-2, differently from hypercapnic ARF in the control group. A significantly higher mortality rate was detected among SARS-CoV-2 patients at Kaplan-Meier survival analysis (1 year mortality: 33.33% in SARS-CoV-2 group vs 3.06% in controls, p <0.0001). Hospitalization was longer in SARS-CoV-2 group than controls (12 days, IQR 7.5–24.5 vs 9 days, IQR 7–14.25, p < 0.01). In conclusion, our study demonstrated that SARS-CoV-2 infection can be considered a potent trigger of COPD exacerbation, able to induce severe hypoxic ARF, which significantly increased the risk of needing positive pressure respiratory support. SARS-CoV-2 profoundly impacted on the mortality, meanwhile prolonging the length of hospital stay. Screening for the presence of viral triggers, particularly of SARS-CoV-2, in case of acute exacerbation of COPD is key, to influence clinical outcomes treatment approach and long-term survival."]},{"key":"dc:title","label":"Title","values":["IMPACT OF SARS-COV-2 RESPIRATORY INFECTION ON CLINICAL OUTCOMES AND NEED FOR NON-INVASIVE VENTILATORY SUPPORT IN ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A SINGLE-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY"]}]}],"canonical_facts":{"dc:contributor":["supervisor: M. Mondoni ; co-supervisor: S. Centanni ; coordinatore del corso di dottorato: M. Del Fabbro","C. Tirelli","MONDONI, MICHELE","DEL FABBRO, MASSIMO"],"dc:creator":["TIRELLI, CLAUDIO"],"dc:date":["2026-03-20"],"dc:description":["Viral and bacterial infections are the main cause of COPD exacerbations, accounting for 25% and 26% of cases respectively. To date no conclusive data are available on the risk of COPD exacerbations triggered by SARS-CoV-2. The present study was primarily aimed to identify the risk of acute respiratory failure (ARF) requiring non-invasive respiratory support up to Continuous Positive Airway Pressure (C-PAP) and Non-Invasive Ventilation (NIV) in patients affected by SARS-CoV-2 triggered COPD exacerbation compared to patients with COPD exacerbations without SARS-CoV-2 infection. Major secondary endpoints included the overall risk of ARF and its stratification according to severity and consequent respiratory support needed. Mortality in the SARS-CoV-2 cohort was also compared to the control group. 238 COPD patients admitted to hospital due to an acute exacerbation of COPD were consecutively enrolled: 120 patients (50.4%) tested positive for SARS-CoV-2 infection at nasopharyngeal swab, while 118 (49.6%) were negative. No significant difference could be demonstrated in the risk of ARF between SARS-CoV-2 and control groups (Relative Risk (RR) 0.89 (p = 0.303), 95% Confidence Interval (CI): 0.73 – 1.06). However, the risk of ARF with the need of ventilatory support up to C-PAP was significantly higher in the SARS-CoV-2 group (RR 4.42 (p = 0.009), 95% CI 1.37 – 14.35).nOn the contrary, the risk of ARF needing NIV was 39% lower in the SARS-CoV-2 group (RR 0.61 (p = 0.003), 95% CI 0.44 – 0.84). This result combined with blood gas analysis values reflected a predominant hypoxemic ARF among SARS-CoV-2, differently from hypercapnic ARF in the control group. A significantly higher mortality rate was detected among SARS-CoV-2 patients at Kaplan-Meier survival analysis (1 year mortality: 33.33% in SARS-CoV-2 group vs 3.06% in controls, p <0.0001). Hospitalization was longer in SARS-CoV-2 group than controls (12 days, IQR 7.5–24.5 vs 9 days, IQR 7–14.25, p < 0.01). In conclusion, our study demonstrated that SARS-CoV-2 infection can be considered a potent trigger of COPD exacerbation, able to induce severe hypoxic ARF, which significantly increased the risk of needing positive pressure respiratory support. SARS-CoV-2 profoundly impacted on the mortality, meanwhile prolonging the length of hospital stay. Screening for the presence of viral triggers, particularly of SARS-CoV-2, in case of acute exacerbation of COPD is key, to influence clinical outcomes treatment approach and long-term survival."],"dc:identifier":["https://hdl.handle.net/2434/1225595"],"dc:language":["eng"],"dc:publisher":["Università degli Studi di Milano"],"dc:relation":["numberofpages:73"],"dc:rights":["info:eu-repo/semantics/openAccess","license:Creative commons","license uri:publisher"],"dc:subject":["SARS-CoV-2","C-PAP","COPD","NIV","mortality","Settore MEDS-07/A - Malattie dell'apparato respiratorio"],"dc:title":["IMPACT OF SARS-COV-2 RESPIRATORY INFECTION ON CLINICAL OUTCOMES AND NEED FOR NON-INVASIVE VENTILATORY SUPPORT IN ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A SINGLE-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY"],"dc:type":["info:eu-repo/semantics/doctoralThesis"]},"updated_at":"2026-07-27T20:19:00Z"}